Immix Biopharma (IMMX) Interest Expenses (2020 - 2026)
Immix Biopharma (IMMX) posted Interest Expenses of $356668.0 for Q1 2026, down 5.56% sequentially from $377682.0 in Q4 2025, and down 18.3% YoY from $436550.0 in Q1 2025.
Immix Biopharma (IMMX) Interest Expenses (2020 - 2026) Analysis & Trends
Immix Biopharma has reported Interest Expenses for 7 years, with the latest figure at $356668.0 in Q1 2026.
- Quarterly Interest Expenses fell 18.3% year-over-year to $356668.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $356668.0 (down 18.3% YoY) and the FY2025 annual result came in at $25.3 million, up 60.43% from the prior year.
- Interest Expenses retreated to $356668.0 in Q1 2026 per IMMX's latest filing, from $377682.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $15.8 million in Q4 2024 and troughed at -$9099.0 in Q4 2022.
- A 5-year average of $2.3 million and a median of $436550.0 in 2025 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses plunged 1128.14% in 2022, then surged 83976.92% in 2023.
- Over 5 years, Interest Expenses stood at -$9099.0 in 2022, then soared by 83976.92% to $7.6 million in 2023, then surged by 106.56% to $15.8 million in 2024, then slumped by 97.6% to $377682.0 in 2025, then fell by 5.56% to $356668.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $356668.0, $377682.0, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 1.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.34 Mn |
| Jun 30, 2026 | 1.34 Mn |
| Mar 31, 2026 | 356,668.00 |
| Mar 31, 2026 | 356,668.00 |
| Dec 31, 2025 | 377,682.00 |
| Dec 31, 2025 | 377,682.00 |
| Sep 30, 2025 | 1.51 Mn |
| Sep 30, 2025 | 1.51 Mn |
| Jun 30, 2025 | 415,741.00 |
| Jun 30, 2025 | 415,741.00 |
| Mar 31, 2025 | 436,550.00 |
| Mar 31, 2025 | 436,550.00 |
| Dec 31, 2024 | 15.76 Mn |
| Dec 31, 2024 | 15.76 Mn |
| Sep 30, 2024 | 1.57 Mn |
| Sep 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Mar 31, 2024 | 522,515.00 |
| Mar 31, 2024 | 522,515.00 |